Eric Shroff - 24 Feb 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: Senior Vice President
Issuer ticker: ABT
Reported as of: 24 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2026, 19:24:53 UTC
Prior SEC filing: 25 Nov 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric Shroff by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Eric Shroff filed Form 4 for ABBOTT LABORATORIES (ABT) on 26 Feb 2026.

Key facts

This page summarizes Eric Shroff's Form 4 filing for ABBOTT LABORATORIES (ABT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Feb 2026, 19:24.

Change

Previous filing in this sequence was filed on 25 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002058129 Primary reporting owner

Shroff Eric

Relationship: Senior Vice President
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Eric Shroff by Jessica H. Paik, Attorney-in-Fact
Signature date: 26 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value: $0
Shares: +10,873
Change %: +36%
Price: $0.000000
Shares after: 41,257
Date: 24 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +44,821
Change %
Price: $0.000000
Shares after: 44,821
Date: 24 Feb 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 44,821
Exercise price: $114.60
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

Footnote F2

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029.